Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Sabatolimab plus spartalizumab showed good tolerability in advanced melanoma or non-small cell lung cancer (NSCLC) patients. Limited anti-tumor activity was observed, but tolerability supports further research in combination therapies.
Area Of Science
- Oncology
- Immunotherapy
- Clinical Trials
Background
- Advanced melanoma and non-small cell lung cancer (NSCLC) often progress after initial treatments.
- Investigating novel combination immunotherapies is crucial for improving patient outcomes.
Purpose Of The Study
- To evaluate the safety and efficacy of sabatolimab in combination with spartalizumab in patients with advanced melanoma or NSCLC.
- To assess the overall response rate, tolerability, and pharmacokinetics of this combination therapy.
Main Methods
- A phase 1-1b/2, open-label, multinational study involving 33 patients with advanced/metastatic melanoma (n=16) or NSCLC (n=17).
- Patients received sabatolimab (800 mg Q4W) plus spartalizumab (400 mg Q4W) until disease progression or unacceptable toxicity.
- Primary outcome was overall response rate; secondary outcomes included safety, tolerability, and pharmacokinetics.
Main Results
- 94% of patients experienced adverse events (AEs), with 46% experiencing grade 3/4 events. Most common grade ≥3 AEs varied by cancer type.
- One patient discontinued treatment due to AEs. Stable disease was observed in 19% of melanoma and 35% of NSCLC patients.
- Median progression-free survival was 1.8 months for melanoma and 1.7 months for NSCLC. Higher immune marker expression correlated with stable disease.
Conclusions
- Sabatolimab plus spartalizumab demonstrated good tolerability in patients with advanced melanoma or NSCLC who progressed on prior anti-PD-1/PD-L1 therapy.
- Limited antitumour activity was noted, but the favorable tolerability profile supports further investigation of sabatolimab in combination regimens.
- The study supports exploring sabatolimab in various combinations and across different tumor types.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.